Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults

CNS Drugs

Volumn 25, Issue 9, 2011, Pages 737-763

  Santosh, Paramala J ^a,b,c   Sattar, Sanjida ^a   Canagaratnam, Myooran ^d  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adults; Adverse drug reactions; Amfetamine mixed salts; Atomoxetine; Attention deficit hyperactivity disorder; Bupropion; Central nervous system stimulants; Dexamfetamine; Dexmethylphenidate; Dopamine release stimulants; Methylphenidate; Modafinil; Nicotinic receptor agonists; Substance related disorders; Tricyclic antidepressants.

Indexed keywords

3 (3,4 DICHLOROPHENYL) 2 (METHOXYMETHYL) 8 AZABICYCLO[3.2.1]OCTANE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; BIPHENTIN; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; DULOXETINE; GALANTAMINE; GUANFACINE; LISDEXAMFETAMINE; LITHIUM; LIVER ENZYME; METHYLPHENIDATE; MODAFINIL; NICOTINE; OXCARBAZEPINE; PAROXETINE; PLACEBO; POZANICLINE; PROPRANOLOL; PSYCHOSTIMULANT AGENT; PYCNOGENOL; REBOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ABNORMAL BEHAVIOR; ACADEMIC ACHIEVEMENT; ADULT; ANGER; ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLURRED VISION; CARDIOVASCULAR EFFECT; CHECKLIST; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DECREASED APPETITE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; IRRITABILITY; JAUNDICE; LIBIDO DISORDER; LICENSING; LIVER TOXICITY; LOW DRUG DOSE; MENSTRUATION DISORDER; MENTAL INSTABILITY; META ANALYSIS; META ANALYSIS (TOPIC); MICTURITION DISORDER; MULTICENTER STUDY (TOPIC); NAUSEA; NERVOUSNESS; OCCUPATION; OPTIMAL DRUG DOSE; OSMOTIC RELEASE ORAL SYSTEM; PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; PULSE PRESSURE; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SEDATION; SEIZURE THRESHOLD; SIDE EFFECT; SKIN IRRITATION; SLEEP DISORDER; SOCIAL INTERACTION; SPHEROIDAL ORAL DRUG ABSORPTION SYSTEM; SUBSTANCE ABUSE; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SWEATING; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THIRST; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; PROPYLAMINES; TREATMENT OUTCOME;

EID: 80052164092     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11593070-000000000-00000     Document Type: Review

References (106)

1. Hill J, Schoener E. Age dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1143-6 (Pubitemid 26299832)
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
3. Mcgough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry 2004; 161: 1948-56 (Pubitemid 39441393)
4. Biederman J, Monuteaux M, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med 2006; 36: 167-79 (Pubitemid 43126141)
5. Spencer T, Biederman J, Wilens TE, et al. Adults with attention-deficit/hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998; 59 Suppl. 7: 59-68 (Pubitemid 28317223)
6. Faraone SV, Biederman J, Spencer T, et al. Attentiondeficit/hyperactivity disorder in adults: an overview. Biol Psychiatry 2000; 48 (1): 9-20
7. Moncrieff J, Timimi S. Is ADHD a valid diagnosis in adults? No. BMJ 2010; 340: c547
8. Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002; 111 (2): 279-89 (Pubitemid 34441206)
9. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007; 190: 402-9 (Pubitemid 46706952)
10. Kessler RC, Adler L, Barkley R. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psych 2006; 163: 716-23 (Pubitemid 44464584)
11. Biederman J, Mick E, Faraone SV, et al. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000; 157 (5): 816-8 (Pubitemid 30249663)
12. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005; 162 (9): 1621-7 (Pubitemid 41318230)
13. Santosh PJ, Canagaratnam M. Paediatric bipolar disorder: an update. Psychiatry 2008; 7 (8): 349-52
14. Weiss MD, Weiss JR. A guide to treatment of adults with ADHD. J Clin Psychol 2004; 65 (3 Suppl.): 27-37
15. Kendall J. Sibling accounts of attention deficit hyperactivity disorder. Fam Process 1999; 38 (1): 117-36
16. Johnston C, Mash EJ. Families of children with attention deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001; 4: 183-207 (Pubitemid 33610771)
17. Barkley RA. Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment. 2nd ed. New York (NY): Guildford Press, 1998
18. Mannuza S, Klein RG. Long term prognosis in attention deficit hyperactivity disorder. Child Adolesc Psych Clin North Am 2000; 9: 711-26
19. Biederman J, Faraone SV. The effects of attention-deficit/hyperactivity disorder on employment and household income. MedGenMed 2006; 8 (3): 12 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1 781280/[Accessed 2011 Jun 29]
20. Matza LS, Paramore C, Prasad M, et al. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005; 3: 5 [online]. Available from URL: http://www.resource-alloca tion.com/content/3/1/5 [Accessed 2011 Jun 29]
21. Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 27 (2): 233-60 (Pubitemid 38452766)
22. US FDA. Information for healthcare professionals: pemoline tablets and chewable tablets (marketed as Cylert) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatients andProviders/ucm126461.htm [Accessed 2011 Jun 29]
23. National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. 2008. Clinical guideline 72 [online]. Available from URL: http://www.nice.org.uk/CG72 [Accessed 2011 Jun 29]
24. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attentiondeficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46 (7): 894-921
25. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 2nd ed. Toronto (ON): CADDRA, 2008
26. Villalba L. Safety review: sudden death with drugs used to treat ADHD [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/ 2006-4210b-07-01-safetyreview.pdf [Accessed 2011 Jul 20]
27. Eli Lilly and Company Ltd. Strattera 10 mg, 18mg, 25 mg, 40 mg, 60mg or 80mg hard capsules: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2011 Jun 29]
28. Bouffard R, Hechtman L, Minde K. The efficacy of 2 different dosages on treatment of adults with attention deficit hyperactivity disorder. Can J Psychiatry 2003; 48 (8): 546-54 (Pubitemid 37280044)
29. Spencer T, Biederman J, Wilens T. A large double blind clinical trial of methylphenidate in the treatment of adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 456-63
30. Kooij JJS, Burger H, Boonstra AM. Efficacy and safety of methylphenidate in 45 adults with attention deficit/hyperactivity disorder: a randomized placebo controlled double blind crossover trial. Psychol Med 2004; 34: 973-82
31. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs. methylphenidate vs. placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001 Sep; 13 (3): 129-34 (Pubitemid 34020146)
32. Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of pycnogenol and methylphenidate in adults with attention deficit hyperactivity disorder (ADHD). J Attent Disord 2002; 6 (2): 49-60
33. Carpentier PJ, De Jong CAJ, Dijkstra BAG, et al. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance misuse disorders. Addiction 2005; 100: 1868-74 (Pubitemid 41775212)
34. Schubiner H, Saules KK, Arfken CL, et al. Double blind placebo controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmol 2002; 10 (3): 286-94 (Pubitemid 34919937)
35. Paterson R, Douglas C, Hallmayer J, et al. A randomised, double blind, placebo controlled trial of dexamphetamine in adults with attention hyperactivity disorder. Aust N Z J Psychiatry 1999; 33: 494-502 (Pubitemid 29386870)
36. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10 (4): 311-20 (Pubitemid 32103907)
37. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 2001 Apr; 21 (2): 223-8 (Pubitemid 32221061)
38. Weiss M, Hechtman L; Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006 Apr; 67 (4): 611-9 (Pubitemid 43764238)
39. Spencer T, Biederman J, Wilens T, et al. Efficacy of amixed amphetamine salts compound in adults with attentiondeficit/hyperactivity disorder. Arch Gen Psychiatry 2001; 58: 775-82 (Pubitemid 32717803)
40. Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24 (1): 24-9 (Pubitemid 38134162)
41. Koesters M, Becker T, Kilian R, et al. Limits of metaanalysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23 (7): 733-44
42. Verster JC, Bekker EM, de RoosM, et al. Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial. J Psychopharmacol 2008; 22 (3): 230-7 (Pubitemid 351847448)
43. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol 2009; 23 (2): 194-205
44. ABPI. Medicines compendium 2006. Leatherhead: Datapharm Communications Ltd., 2006
45. Levin ED, Conners CK, Silva D, et al. Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. Exp Clin Psychopharmacol 2001; 9 (1): 83-90 (Pubitemid 32852217)
46. Rosler M, Fischer R. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259 (2): 120-9
47. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder: results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007 Feb; 68 (2): 268-77 (Pubitemid 46362649)
48. Biederman J, Mick E, Surman C, et al. A randomised placebo controlled trial of OROS methylphenidate in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2006; 59: 829-35
49. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008; 63 (10): 981-9
50. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attentiondeficit/hyperactivity disorder: a randomized, placebocontrolled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29 (3): 239-47
51. Reimherr FW, Williams ED. A double-blind, placebocontrolled, crossover study of osmotic release oral system methylphenidate in adults withADHDwith assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68 (1): 93-101 (Pubitemid 46220130)
52. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 137-48 (Pubitemid 41821797)
53. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD: double blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87: 20-9 (Pubitemid 46074379)
54. Konstenius M, Jayaram-Lindstrom N, Beck O, et al. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010; 108 (1-2): 130-3
55. Spencer T, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007; 61: 1380-7 (Pubitemid 46855767)
56. Weisler RH, Biederman J, Spencer T, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006; 11 (8): 625-39 (Pubitemid 44253518)
57. Spencer TJ, Adler LA. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebocontrolled study. J Clin Psychiatry 2008; 69 (9): 1437-48
58. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attentiondeficit/hyperactivity disorder. J Clin Psychiatry 2008 Sep; 69 (9): 1364-73
59. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15 (8): 476-95 (Pubitemid 46020533)
60. Novartis. Ritalin-and Ritalin SR®: prescribing information [online]. Available from URL: http://www.phar ma.us.novartis.com/product/pi/pdf/ritalin- ritalin-sr.pdf [Accessed 2011 Jun 29]
61. Novartis. Ritalin LA®: prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com:80/pro duct/pi/pdf/ritalin-la.pdf [Accessed 2011 Jun 29]
62. Chronis-Tuscano A, Seymour KE, SteinMA, et al. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. J Clin Psychiatry 2008; 69 (12): 1938-47
63. Adler LA, Spencer T, McGough JJ, et al. Long-term effectiveness and safety of dexmethylphenidate extendedrelease capsules in adult ADHD. J Atten Disord 2009; 12 (5): 449-59
64. Weisler R, Young J, Mattingly G, et al. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. CNS Spectr 2009; 14 (10): 573-85
65. Starr HL. Serious cardiovascular AEs CONCERTA®postmarketing August 2000 to December 2005: CONCERTA®(methylphenidate HCl) extended-release tablets. United States Food and Drug Administration Advisory Committee, March 22, 2006 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4210s-16-Mc Neil-Presentation-files/frame.htm [Accessed 2011 Aug 10]
66. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2009; 70 (12): 1652-61
67. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder.AmJ Psychiatry 1998; 155 (5): 693-5 (Pubitemid 28225414)
68. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomised placebo-controlled studies. Biol Psychiatry 2003; 53: 112-20 (Pubitemid 36126473)
69. Adler LA, Spencer T, Brown TE, et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 2009; 29 (1): 44-50
70. Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26 (3): 212-21
71. Wilens T, Spencer T, Biederman J, et al. A controlled clinical trial of buproprion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001 Feb; 158 (2): 282-8 (Pubitemid 32116526)
72. Wilens T,Haight BR, Horrigan JP, et al. Buproprion XL in adults with attention-deficit/hyperactivity disorder: a randomized placebo-controlled study. Biol Psychiatry 2005; 57: 793-801 (Pubitemid 40487924)
73. Wilens T, Biederman J, Spencer T, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999 Dec; 156 (12): 1931-7
74. Wilens T, Verlinden MH, Adler LA, et al. ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study. Biol Psychiatry 2006; 59: 1065-70 (Pubitemid 43849655)
75. Biederman J, Mick E, Faraone SV, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/ hyperactivity disorder: a pilot study. J Clin Psychopharmacol 2006 Apr; 26 (2): 163-6 (Pubitemid 43740340)
76. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attentiondeficit/hyperactivity disorder. J Clin Psychopharmacol 2001; 21 (2): 223-8 (Pubitemid 32221061)
77. Wilens TE, Klint T, Adler L, et al. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behav Brain Funct 2008; 4: 24 [online]. Available from URL: http://www.behavioraland brainfunctions.com/content/pdf/1744-9081-4-24.pdf [Accessed 2011 Jul 29]
78. Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35: 1491-501 (Pubitemid 26360935)
79. Reimherr FW, Marchant BK, Strong RE, et al. Emotional dysregulation in adult ADHD and response to atomoxetine. Biol Psychiatry 2005; 58: 125-31 (Pubitemid 41008129)
80. Johnson M, Cederlund M, Rastam M, et al. Open-label trial of atomoxetine hydrochloride in adults with ADHD. J Atten Disord 2010; 13 (5): 539-45
81. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults withADHD: final report of a 4-year study. J Atten Disord 2008; 12 (3): 248-53
82. Wilens TE, Adler LA, Weiss MD, et al. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug Alcohol Depend 2008; 96 (1-2): 145-54
83. Adler L, Dietrich A, Reimherr F, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry 2006 Apr-Jun; 18 (2): 107-13 (Pubitemid 43879898)
84. Wilens TE, Biederman J, Prince J, et al. Six-week, doubleblind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153 (9): 1147-53 (Pubitemid 26299833)
85. Biederman J, Spencer T. Non-stimulant treatments for ADHD. EurChild Adolesc Psychiatry 2000; 9 Suppl. 1: I51-9
86. Abramowicz M. Sudden death in children treated with a tricyclic antidepressant. Med Letter 1990; 32: 37-40
87. Riddle MA, Nelson JC, Kleinman CS, et al. Sudden death in children receiving Norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1991; 30: 104-8
88. Milberger S, Biederman J, Faraone SV, et al. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry 1997; 36 (1): 37-44 (Pubitemid 27024226)
89. Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7 (3): 373-8 (Pubitemid 26032582)
90. Wilens TE, Adamson J, Sgambati S, et al. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict 2007; 16 Suppl. 1: 14-21; quiz 22-13
91. Hornig-Rohan M, Amsterdam JD. Venlafaxine versus stimulant therapy in patients with dual diagnosis ADD and depression. Progr Neuropsychopharmacol Biol Psychiatry 2002; 26: 585-9 (Pubitemid 34252955)
92. Arabgol F, Panaghi L, Hebrani P. Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 2009 Jan; 18 (1): 53-9
93. Tourjman SV, Bilodeau M. Improvement with duloxetine in an adult ADHD patient. J Atten Disord 2009; 13 (1): 95-6
94. Dorrego MF, Canevaro L, Kuzis G, et al. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. J Neuropsychiatry Clin Neurosci 2002; 14 (3): 289-95 (Pubitemid 34827684)
95. Davids E, Kis B, Specka M, et al. A pilot clinical trial of oxcarbazepine in adults with attention-deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30 (6): 1033-8 (Pubitemid 43928218)
96. Mattes JA. Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986; 6 (5): 299-302 (Pubitemid 17206874)
97. Peterson K, McDonagh MS, Fu R, et al. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl) 2008; 197 (1): 1-11
98. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010 Jun; 71 (6): 754-63
99. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using metaanalysis. Eur Child Adolesc Psychiatry 2010; 19 (4): 353-64
100. Corrigan B. Attention deficit hyperactivity disorder in sport: a review. Int J Sports Med 2003 Oct; 24 (7): 535-40 (Pubitemid 37211222)
101. Davidson MA. ADHD in adults: a review of the literature. J Atten Disord 2008; 11 (6): 628-41
102. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD: results of an open study of 43 patients. J Atten Disord 2006; 10: 150-9 (Pubitemid 44622769)
103. Murphy K. Psychosocial treatments for ADHD in teens and adults: a practice friendly review. J Clin Psychol 2005; 61: 607-19 (Pubitemid 40776547)
104. Hesslinger B, Tebartz van Elst L, Nyberg E, et al. Psychotherapy of attention deficit hyperactivity disorder in adults: a pilot study using a structured skills training program. Eur Arch Psychiatry Clin Neurosci 2002 Aug; 252 (4): 177-84 (Pubitemid 36056674)
105. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry 2004; 65 Suppl. 3: 27-37
106. Rosler M, Retz W, Retz-Junginger P, et al. Prevalence of attention deficit/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004; 254 (6): 365-71 (Pubitemid 40192991)